問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

693Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1743Cases

2026-07-01 - 2028-11-30

Phase II

Not yet recruiting
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Advanced Gastrointestinal (GI) Cancers

  • Condition/Disease

    Gastrointestinal Cancers

  • Test Drug

    Rina‑S

Participate Sites
5Sites

Not yet recruiting1Sites

2018-07-30 - 2020-09-30

Phase III

Completed
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer Metastatic Gastric Adenocarcinoma or Cancer Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
9Sites

Recruiting6Sites

Terminated1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

2018-07-01 - 2023-06-02

Phase III

Completed
A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

  • Condition/Disease

    Early Breast Cancer

  • Test Drug

    PHESGO

Participate Sites
4Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

陳訓徹
Linkou Chang Gung Medical Foundation

2018-06-26 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion

  • Condition/Disease

    Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

  • Test Drug

    Venetoclax

Participate Sites
7Sites

Recruiting6Sites

2024-07-01 - 2027-11-30

Phase II

Active
A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Lutikizumab (ABT-981) Lutikizumab (ABT-981)

Participate Sites
4Sites

Recruiting4Sites

2019-07-19 - 2022-01-01

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    NA

Participate Sites
6Sites

Recruiting6Sites

2017-11-01 - 2020-03-19

Phase II/III

Completed
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC)and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    MOR00208

Participate Sites
11Sites

Not yet recruiting7Sites

Terminated3Sites

白禮源
China Medical University Hospital-Taipei

未分科

2018-08-01 - 2032-07-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≧ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    RO5424802(Alectinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

2018-01-01 - 2023-05-12

Phase II/III

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis (UC)

  • Test Drug

    Risankizumab

Participate Sites
6Sites

Recruiting6Sites

2018-06-01 - 2024-12-31

Phase III

Completed
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children

  • Condition/Disease

    Enterovirus Infections

  • Test Drug

    "安拓伏"腸病毒71型疫苗

Participate Sites
8Sites

Terminated7Sites

1 6 7 8 9 10 175
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB